TGNA.F Transgene SA

Healthcare Biotechnology Frankfurt Exchange
0.7000 EUR
Close of Nov 13, 2026
0.5970 1.31
Market cap
EUR 195M
P/E
-
P/B
1.85x
ROE
-30.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is TGNA.F undervalued?

Graham number

The Graham number of Transgene SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Transgene SA fundamental analysis

No fundamental analysis for Transgene SA yet.

Transgene SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Transgene SA

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical tr…

Full company profile